Cosmo Feilding Mellen – currently Beckley's chief executive, who is slated to serve as chief strategy officer of the merged ...

The analysis by the Royal College of Paediatrics and Child Health suggests the main barriers to access are factors like ...

A new task force comprising staff from the UK medicines regulator, the MHRA, and cost-effectiveness arbiter NICE – with the ...

Amgen acquired Five Prime in 2021 on the back of the phase 2 FIGHT trial of bemarituzumab which achieved significant ...

AbbVie has agreed to buy Capstan Therapeutics for up to $2.1 billion, expanding its pipeline with a potential first-in-class ...

Hikma's announcement ties into that sentiment, coming with the strap line: "America Leans on Hikma: Quality Medicines ...

Galapagos announces leadership transition. European biotechnology company Galapagos completed a significant leadership ...

In the case of the amyloid drugs, Eisai Biogen's Leqembi (lecanemab) and Eli Lilly's Kisunla (donanemab) – there are also ...

BioCryst has agreed to sell its European business based on hereditary angioedema (HAE) therapy Orladeyo to Italy's Neopharmed ...

GRIN-related neurodevelopmental disorder (GRIN-NDD) is a family of rare, genetically defined neurodevelopmental disorders ...

ASCO 2025 spotlighted new data across haematologic cancers this year. To discuss announcements in liquid cancers further, as opposed to solid tumours, pharmaphorum spoke with Dr Lore Gruenbaum, chief ...